Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

OptimizeRx (OPRX) EPS (Weighted Average and Diluted) (2017 - 2025)

OptimizeRx (OPRX) has disclosed EPS (Weighted Average and Diluted) for 15 consecutive years, with $0.26 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 6197.64% to $0.26 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.26 through Dec 2025, up 123.64% year-over-year, with the annual reading at $0.27 for FY2025, 124.55% up from the prior year.
  • EPS (Weighted Average and Diluted) hit $0.26 in Q4 2025 for OptimizeRx, up from $0.04 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.26 in Q4 2025 to a low of -$0.5 in Q3 2024.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$0.12 across 5 years, with a median of -$0.15 in 2023.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): plummeted 8210.15% in 2022 and later surged 6197.64% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at $0.03 in 2021, then crashed by 166.67% to -$0.02 in 2022, then tumbled by 1100.0% to -$0.24 in 2023, then surged by 98.22% to -$0.0 in 2024, then soared by 6197.64% to $0.26 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for OPRX at $0.26 in Q4 2025, $0.04 in Q3 2025, and $0.08 in Q2 2025.